Literature DB >> 8270496

Synthesis and biological activity of derivatives of glycopeptide antibiotics eremomycin and vancomycin nitrosated, acylated or carbamoylated at the N-terminal.

A Y Pavlov1, T F Berdnikova, E N Olsufyeva, E I Lazhko, I V Malkova, M N Preobrazhenskaya, R T Testa, P J Petersen.   

Abstract

Nitrosation, carbamoylation or acylation of the glycopeptide antibiotics eremomycin or vancomycin produced series of derivatives substituted at the N-terminus of the peptides. Though the modified amino group in these derivatives is not capable of protonation, N-nitroso derivatives retain antibacterial activity in vitro and in vivo. N-Carbamoyleremomycin has low activity, and N-Cbz-eremomycin and N-Boc-eremomycin are devoid of antibacterial activity, both in vitro and in vivo.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8270496     DOI: 10.7164/antibiotics.46.1731

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN: 0021-8820            Impact factor:   2.649


  5 in total

1.  The effect of environment on the recognition and binding of vancomycin to native and resistant forms of lipid II.

Authors:  ZhiGuang Jia; Megan L O'Mara; Johannes Zuegg; Matthew A Cooper; Alan E Mark
Journal:  Biophys J       Date:  2011-12-07       Impact factor: 4.033

2.  N-Terminus Alkylation of Vancomycin: Ligand Binding Affinity, Antimicrobial Activity, and Site-Specific Nature of Quaternary Trimethylammonium Salt Modification.

Authors:  Zhi-Chen Wu; Nicholas A Isley; Dale L Boger
Journal:  ACS Infect Dis       Date:  2018-08-08       Impact factor: 5.084

3.  Synthesis and evaluation of vancomycin aglycon analogues that bear modifications in the N-terminal D-leucyl amino acid.

Authors:  Christine M Crane; Dale L Boger
Journal:  J Med Chem       Date:  2009-03-12       Impact factor: 7.446

4.  Inhibition of feline (FIPV) and human (SARS) coronavirus by semisynthetic derivatives of glycopeptide antibiotics.

Authors:  Jan Balzarini; Els Keyaerts; Leen Vijgen; Herman Egberink; Erik De Clercq; Marc Van Ranst; Svetlana S Printsevskaya; Eugenia N Olsufyeva; Svetlana E Solovieva; Maria N Preobrazhenskaya
Journal:  Antiviral Res       Date:  2006-04-06       Impact factor: 5.970

Review 5.  The next ten stories on antiviral drug discovery (part E): advents, advances, and adventures.

Authors:  Erik De Clercq
Journal:  Med Res Rev       Date:  2011-01       Impact factor: 12.944

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.